Nathalie A. Lokker
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Colorectal Cancer Treatments and Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.(2002)
- → PDGF-D, a new protease-activated growth factor(2001)416 cited
- → CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)(2002)307 cited
- → Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.(1992)296 cited
- → Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations(2006)194 cited
- → Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1(1993)90 cited
- → Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial(2013)90 cited
- → A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer(2012)85 cited
- → Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518(2004)80 cited
- → Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer(2019)78 cited